First, oncogenic KRAS mutations were associated with chemoresistance and poor prognosis in NSCLC, also by controlling the NFE2L2 gene transcription through a direct link of KRAS to a TPA response element (TRE) located in the NFE2L2 promoter [33]. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.